CSO
Huahui Health Biotech
Beijing, China (People's Republic)
Dr. Ye Bin is a seasoned expert in biomarker-driven translational medicine, dedicated to advancing drug development through innovative approaches. With hands-on experience in biomarker data integration, validation, enrichment trial planning, and regulatory engagement, he has contributed to two successful novel drug NDA submissions—either utilizing biomarker enrichment strategies or incorporating biomarker endpoints. This demonstrates his ability to translate scientific insights into impactful therapeutic solutions.
Throughout his industry career, Dr. Ye has held leadership roles spanning early-phase to pivotal clinical trials. A notable achievement includes implementing biomarker-enrichment strategies in pivotal trials that supported regulatory approval of novel therapies. His expertise stems from multiple studies in Novartis and global CROs on biomarker development programs, informing Phase I-II clinical trials across diverse therapeutic areas.
With over a decade of academic experience at Harvard Medical School, Dr. Ye led cross-functional teams in molecular cancer biology, epidemiology, clinical cancer biomarkers, statistics, and medical engineering (Harvard-MIT hub), contributing to multiple NIH-NCI programs. He independently led interdisciplinary translational projects, authoring over 40 publications and securing multiple patents. Additionally, he actively delivers invited presentations at global and local China bio-conferences. Dr. Ye earned his Ph.D. in Biochemistry and Molecular Biology from the Weizmann Institute of Science in 1998.
Disclosure information not submitted.
Composite Non-Invasive Testing Biomarker Enrichment in HBV-aHCC with Poor Prognosis
Tuesday, November 11, 2025
9:30 AM - 10:00 AM CT